Liu X, et al. - A CHOPE/G regimen (cyclophosphamide, pirarubicin, vincristine, prednisolone, and etoposide alternating with a gemcitabine-based regimen) was designed as the first-line treatment of peripheral T-cell lymphomas (PTCLs) and was compared with CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) and CHOPE (CHOP plus etoposide) regimen to assess the optimal chemotherapy regimen. Researchers retrospectively analyzed 116 previously untreated PTCL patients receiving CHOP (N = 46), CHOPE (N = 46), or CHOPE/G (N = 24) regimen at Peking University Cancer Hospital from 2009 to 2017. CHOPE regimen displayed improved efficacy and survival when compared with CHOP alone. The addition of gemcitabine in the front-line therapy led to more adverse events without survival benefit.